Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Meta-Analysis Shows Efficacy, Safety of CAR T-Cell Therapy in R/R Mantle Cell Lymphoma

October 14th 2024

CAR T-cell therapy demonstrated efficacy and manageable safety in mantle cell lymphoma in a systematic review of prospective and real-world studies.

The OncFive: Top Oncology Articles for the Week of 9/29

October 5th 2024

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

OncLive’s September Roundup of Key FDA Approvals in Oncology

October 4th 2024

Here is your snapshot of all treatment options that the FDA approved in September 2024.

FDA Grants Priority Review to Acalabrutinib in Treatment-Naive Mantle Cell Lymphoma

October 3rd 2024

The FDA granted priority review to acalabrutinib for previously untreated mantle cell lymphoma.

Dr Koff on Frontine and Maintenance Treatment Decision-Making in MCL

September 27th 2024

Jean L. Koff, MD, MS, discusses factors that influence treatment decision-making for patients with MCL in the frontline and maintenance settings.

Novel BTK Inhibitor LP-168 Under Investigation in China for R/R Mantle Cell Lymphoma

September 20th 2024

The next-generation BTK inhibitor LP-168 is being investigated in the phase 2 ROCK-1 trial in patients with relapsed/refractory mantle cell lymphoma.

Zanubrutinib/Rituximab Induction May Be Safe and Effective in Newly Diagnosed Mantle Cell Lymphoma

September 19th 2024

The chemotherapy-free induction regimen of zanubrutinib plus rituxumab produced response rates in patients with newly diagnosed mantle cell lymphoma.

First-Line Zanubrutinib/Obinutuzumab Shows Efficacy, Safety in Older MCL

September 19th 2024

The frontline combination of obinutuzumab and zanubrutinib demonstrated efficacy and safety in older patients with mantle cell lymphoma.

Dr Gordon on Shifts in the R/R MCL Treatment Paradigm

September 18th 2024

Leo I. Gordon, MD, discusses the evolution of the treatment paradigm in relapsed/refractory mantle cell lymphoma.

Dr Danilov on Ongoing MCL Clinical Trials

September 11th 2024

Alexey Danilov, MD, PhD, discusses ongoing investigations taking place to improve the treatment of patients with mantle cell lymphoma.

FDA Approves Bortezomib Injectable for Multiple Myeloma and MCL

September 6th 2024

The FDA has approved a new presentation of bortezomib for subcutaneous or intravenous administration.

Dr Koff on the Role of Covalent BTK Inhibitors and Pirtobrutinib in MCL

September 5th 2024

Jean L. Koff, MD, MS, discusses the role of covalent BTK inhibitors in the treatment of mantle cell lymphoma.

Dr Kamdar on the Benefit of Liso-Cel Therapy Across Lymphoma Subgroups

August 28th 2024

Manali Kamdar, MD, discusses which populations of lymphoma subtypes, such as MCL, may derive the most benefit from liso-cel treatment.

Subgroup Analysis Makes the Case for Earlier Liso-Cel Administration in R/R MCL

August 13th 2024

Manali Kamdar, MD, discusses responses with liso-cel according to prior lines of therapy and BTK inhibitor exposure in mantle cell lymphoma.

Orelabrutinib Plus Lenalidomide and Rituximab Demonstrates Efficacy in Frontline MCL

August 9th 2024

Orelabrutinib in combination with lenalidomide and rituximab was safe and active in treatment-naive mantle cell lymphoma.

Ibrutinib Plus Lenalidomide and Rituximab Demonstrates Activity in R/R MCL

August 7th 2024

The combination of ibrutinib, lenalidomide, and rituximab elicited a high response rate in patients with relapsed/refractory mantle cell lymphoma.

Chemotherapy-Free Approaches Are at the Forefront in MCL

August 5th 2024

Alexey Danilov, MD, PhD, highlights non-chemotherapy options for the treatment of mantle cell lymphoma and expands on ongoing research in hematologic malignancies.

Study Shows Real-World Benefit of Rituximab Maintenance After Frontline BR in Mantle Cell Lymphoma

July 23rd 2024

Rituximab maintenance therapy following frontline bendamustine plus rituximab improved EFS, EFS2, and OS vs no maintenance therapy in patients with MCL.

Ibrutinib Plus Venetoclax Generates Durable CRs in TP53+ Mantle Cell Lymphoma

July 18th 2024

Ibrutinib plus venetoclax produced durable complete responses in TP53-mutated mantle cell lymphoma.

The Shifting MCL Treatment Paradigm Raises Sequencing Questions

July 15th 2024

Tycel Phillips, MD, expands on the treatment paradigm for patients with mantle cell lymphoma, highlighting recent data read-outs and FDA approvals/withdrawals